Hanmi Pharmaceutical Completes $100M+ Acquisition of Aptose Biosciences — Aptose Biosciences Inc.

Event summary

Hanmi Pharmaceutical completed its acquisition of Aptose Biosciences for C$2.41 per share, a 28% premium over Aptose’s 30-day VWAP.
The deal closed on June 30, 2026, following shareholder and regulatory approvals secured in March 2026.
Aptose’s common shares are expected to be delisted from the TSX by July 3, 2026.
Aptose is a clinical-stage oncology company focused on AML treatments, while Hanmi is a South Korea-based pharmaceutical firm with a global pipeline.

The big picture

This acquisition reflects Hanmi’s push into precision oncology, particularly in hematology. The deal underscores the trend of Asian pharmaceutical firms acquiring Western biotechs to bolster their pipelines with novel therapies. Aptose’s focus on AML aligns with Hanmi’s strategy of addressing high-unmet medical needs across multiple therapeutic areas.

What we're watching

Integration Strategy: How Hanmi will integrate Aptose’s clinical-stage assets into its global pipeline, particularly tuspetinib for AML.
Regulatory Compliance: Whether the delisting and termination of public reporting requirements proceed smoothly by July 3, 2026.
Pipeline Progression: The pace at which Hanmi advances Aptose’s triplet therapy for newly diagnosed AML through clinical trials.